Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MLKL | Q8NB16 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770571 | 0.91 | KMT2A (0.46) | MEN1HTTKMT2AMAOBMAOA | |
| SCHEMBL14770587 | 0.91 | MEN1 (0.46) | MEN1HTTKMT2AMAOBMAOA | |
| SCHEMBL14770568 | 0.90 | MEN1 (0.47) | MEN1HTTKMT2AMAOBNPC1 | |
| SCHEMBL12065259 | 0.88 | FFAR1 (0.44) | MEN1HTTKMT2AMAOBMAOA | |
| SCHEMBL14770590 | 0.87 | HTT (0.43) | MEN1HTTKMT2AMAOBFFAR1 | |
| SCHEMBL14770595 | 0.84 | MAOA (0.44) | MEN1HTTKMT2AMAOANPC1 | |
| SCHEMBL14770580 | 0.84 | FFAR1 (0.46) | MEN1HTTKMT2AMAOBMAOA | |
| SCHEMBL14770535 | 0.83 | MEN1 (0.53) | MEN1HTTKMT2ANPC1RAB9A | |
| SCHEMBL14770579 | 0.81 | CYP1A2 (0.46) | MEN1HTTKMT2AMAOBMAOA | |
| SCHEMBL14770583 | 0.81 | MEN1 (0.44) | MEN1HTTKMT2AMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | MEN1 2676/4885HTT 3959/4885KMT2A 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.